Yesterday, the FDA ordered GlaxoSmithKline (GSK) to stop selling diabetes drug Avandia in retail pharmacies starting later this year.
Once the best selling diabetes drug in the world with $3 billion in annual revenue, GSK still generated $680 million in Avandia sales last year even after the significant risks of this drug became known. In September 2010, the FDA significantly limited the situations where Avandia and drugs made with rosiglatazone could be used in response to data that suggested an elevated risk of heart attacks. Soon, Avandia will be pulled from the shelves completely.
To read the entire Bloomberg article, click here: Glaxo’s Diabetes Drug Avandia Pulled from U.S. Pharmacies
Click here to read the FDA Avandia Safety Announcement
Click here to learn more about the Brandi Law Firm Avandia Attorneys and the risks associated with Avandia use.